Specifically, TET2 has been frequently reported to be mutated in hematological malignancies (85), including angioimmunoblastic T cell lymphoma (AITL) (86–88) and peripheral T cell lymphoma, non-otherwise specified (PTCL-NOS) (89). The gene discussed is TET2; the disease is cancer.